MicroRNA-328-3p inhibits the tumorigenesis of bladder cancer through targeting ITGA5 and inactivating PI3K/AKT pathway

被引:5
|
作者
Yan, T. [1 ]
Ye, X-X [2 ]
机构
[1] Ningbo Univ, Med Coll, Yinzhou Hosp, Dept Urinary Surg, Ningbo, Zhejiang, Peoples R China
[2] Shanghai Univ Med & Hlth Sci, Shanghai Peoples Hosp East 6, Dept Urinary Surg, Shanghai, Peoples R China
关键词
miR-328-3p; ITGA5; Bladder cancer; PI3K/AKT pathway; HEPATOCELLULAR-CARCINOMA; REGULATING PI3K/AKT; CELL-GROWTH; INVASION; EXPRESSION; ACTIVATION; MIGRATION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Previous studies have shown that microRNA-328-3p (miR-328-3p) is involved in tumorigenesis of many human cancers. However, the specific function of miR-328-3p remains unclear in bladder cancer (BC). Therefore, this research was designed to investigate the role of miR-328-3p in BC. PATIENTS AND METHODS: Expressions of miR-328-3p and integrin alpha 5 (ITGA5) were measured by quantitative Real-time polymerase chain reaction (qRT-PCR). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and transwell assays were used to explore the function of miR-328-3p in BC. The expression of the corresponding genes was observed via Western blot and immunocytochemical assays. The dual luciferase assay was applied to verify the relationship between miR-328-3p and ITGA5. Tumor growth was measured via xenograft tumor formation assay. RESULTS: Downregulation of miR-328-3p was identified in BC tissues, which predicted poor prognosis in BC patients. Moreover, miR-328-3p suppressed cell proliferation, migration and invasion in BC through targeting ITGA5. Furthermore, miR-328-3p inhibited epithelial-mesenchymal transition (EMT) and inactivated PI3K/AKT pathway in BC. Besides that, miR-328-3p was found to inhibit tumor growth of BC. CONCLUSIONS: MiR-328-3p inhibited tumorigenesis of BC through targeting ITGA5 and inactivating the PI3K/AKT pathway.
引用
收藏
页码:5139 / 5148
页数:10
相关论文
共 50 条
  • [21] MEG3 overexpression inhibits the tumorigenesis of breast cancer by downregulating miR-21 through the PI3K/Akt pathway
    Zhu, Mingzhi
    Wang, Xiaochun
    Gu, Yuanting
    Wang, Fang
    Li, Lin
    Qiu, Xinguang
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 661 : 22 - 30
  • [22] MicroRNA-30a-3p inhibits the progression of lung cancer via the PI3K/AKT by targeting DNA methyltransferase 3a
    Wei, Desheng
    Yu, Guangmao
    Zhao, Yeping
    ONCOTARGETS AND THERAPY, 2019, 12 : 7015 - 7024
  • [23] Knockdown of CCNB2 inhibits the tumorigenesis of gastric cancer by regulation of the PI3K/Akt pathway
    Hu, Ming
    Tao, Pengxian
    Wang, Yongfeng
    Zhu, Chengzhang
    Ma, Yuntao
    Liu, Xiaolong
    Cai, Hui
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [24] miR-30a-3p inhibits the proliferation of liver cancer cells by targeting DNMT3a through the PI3K/AKT signaling pathway
    Chen, Qiong
    Gao, Yuan
    Yu, Qin
    Tang, Feng
    Zhao, Pei-Wei
    Luo, Su-Kun
    Lin, Ju-Sheng
    Mei, Hong
    ONCOLOGY LETTERS, 2020, 19 (01) : 606 - 614
  • [25] MicroRNA-199a-3p inhibits angiogenesis by targeting the VEGF/PI3K/AKT signalling pathway in an in vitro model of diabetic retinopathy
    Wang, Ling
    Liu, Wei-Xian
    Huang, Xiong-Gao
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 116
  • [26] Targeting the PI3K pathway in cancer
    Workman, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S80 - S80
  • [27] Targeting the PI3K pathway in cancer
    Mills, GB
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S4 - S4
  • [28] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [29] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
    Cidado, Justin
    Park, Ben Ho
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2012, 17 (3-4) : 205 - 216
  • [30] Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
    Mortazavi, Motahareh
    Moosavi, Fatemeh
    Martini, Miriam
    Giovannetti, Elisa
    Firuzi, Omidreza
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 176